Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZURA Stock Forecast 2026-2027
$5.06
Current Price
$488.64M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ZURA Price Targets
+413.8%
To High Target of $26.00
+196.4%
To Median Target of $15.00
+117.4%
To Low Target of $11.00
ZURA Price Momentum
-7.8%
1 Week Change
+37.5%
1 Month Change
+289.2%
1 Year Change
-3.4%
Year-to-Date Change
-32.0%
From 52W High of $7.44
+301.6%
From 52W Low of $1.26
📊 TOP ANALYST CALLS
Did ZURA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Zura Bio is one of their latest high-conviction picks.
Latest ZURA Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ZURA has a bullish consensus with a median price target of $15.00 (ranging from $11.00 to $26.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $5.06, the median forecast implies a 196.4% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZURA Analyst Ratings
8
Buy
0
Hold
0
Sell
ZURA Price Target Range
Low
$11.00
Average
$15.00
High
$26.00
Current: $5.06
Latest ZURA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZURA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2026 | William Blair | Matt Phipps | Outperform | Initiates | $N/A |
| Jul 1, 2026 | Wedbush | Martin Fan | Outperform | Reiterates | $15.00 |
| Mar 23, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 20, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| Feb 9, 2026 | Wedbush | Outperform | Initiates | $N/A | |
| Nov 14, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 13, 2025 | Clear Street | Buy | Initiates | $N/A | |
| Sep 30, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 19, 2025 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Aug 15, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Aug 15, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| May 9, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Apr 3, 2025 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Mar 26, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Mar 26, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Mar 26, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 24, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Dec 11, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Nov 18, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Nov 11, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A |
Zura Bio Ltd. (ZURA) Competitors
The following stocks are similar to Zura Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zura Bio Ltd. (ZURA) Financial Data
Zura Bio Ltd. has a market capitalization of $488.64M with a P/E ratio of 7.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -41.0%.
Valuation Metrics
Market Cap
$488.64M
Enterprise Value
$259.84M
P/E Ratio
7.9x
PEG Ratio
0.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+46.9%
Current Ratio
19.3x
Debt/Equity
0.0x
ROE
-41.0%
ROA
-25.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zura Bio Ltd. (ZURA) Business Model
About Zura Bio Ltd.
What They Do
Develops novel antibodies for autoimmune diseases.
Business Model
Zura Bio Ltd. operates as a clinical-stage immunology company that generates revenue through the development of dual-pathway antibodies. The company’s business model revolves around advancing its proprietary pipeline of therapies, including those in various phases of clinical trials, which are designed to treat autoimmune and inflammatory diseases. By focusing on innovative treatment strategies, Zura aims to address unmet medical needs and improve patient outcomes.
Additional Information
The company's lead asset, tibulizumab, is currently in Phase 2 trials, while other candidates like crebankitug and torudokimab are poised for Phase 2 readiness. Zura Bio is led by experienced biotechnology entrepreneurs and professionals, positioning it well within the competitive landscape of immunology. The dual antagonism strategy employed by Zura is aimed at enhancing treatment efficacy and safety for a diverse patient population.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
30
CEO
Mr. Robert Lisicki
Country
United States
IPO Year
2023
Website
zurabio.comZura Bio Ltd. (ZURA) Latest News & Analysis
Latest News
Quick Summary
William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, highlighting the promising potential of its lead candidate, tibulizumab, in severe autoimmune diseases.
Why It Matters
William Blair's Outperform rating on Zura Bio highlights strong growth potential for tibulizumab, signaling optimism that could drive investor interest and stock performance.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) announced the completion of enrollment for its Phase 2 TibuSHIELD trial of tibulizumab, exceeding its target with 247 participants.
Why It Matters
Zura Bio's successful Phase 2 trial enrollment for tibulizumab signals strong potential for drug development, impacting future valuations and market confidence. Positive results may lead to increased stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
2 months ago
Quick Summary
Zura Bio Limited appointed Muzammil Mustufa as Chief Business Officer to lead corporate strategy, business development, and investor relations efforts.
Why It Matters
Muzammil Mustufa's appointment as CBO indicates a strategic focus on growth and investor engagement for Zura Bio, which could enhance the company's market position and attract investment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) granted an inducement option to purchase 600,000 Class A Ordinary Shares to new Chairman Muzammil Mustufa on May 13, 2026.
Why It Matters
The grant of stock options to the new chairman suggests confidence in future growth, potentially influencing share price and investor sentiment positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) reported Q1 2026 financial results, highlighting a strengthened balance sheet and team as it advances its development of medicines for autoimmune diseases.
Why It Matters
Zura Bio's strong financial results and enhanced team signal potential for growth and innovation, which could boost investor confidence and stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) reported strong progress in its Phase 2 programs and financial results for the year ended December 31, 2025, focusing on treatments for autoimmune diseases.
Why It Matters
Zura Bio's strong execution and advancements in Phase 2 programs signal potential for future growth, impacting investor confidence and stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ZURA Stock
What is Zura Bio Ltd.'s (ZURA) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Zura Bio Ltd. (ZURA) has a median price target of $15.00. The highest price target is $26.00 and the lowest is $11.00.
Is ZURA stock a good investment in 2027?
According to current analyst ratings, ZURA has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZURA stock?
Wall Street analysts predict ZURA stock could reach $15.00 in the next 12 months. This represents a 196.4% increase from the current price of $5.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zura Bio Ltd.'s business model?
Zura Bio Ltd. operates as a clinical-stage immunology company that generates revenue through the development of dual-pathway antibodies. The company’s business model revolves around advancing its proprietary pipeline of therapies, including those in various phases of clinical trials, which are designed to treat autoimmune and inflammatory diseases. By focusing on innovative treatment strategies, Zura aims to address unmet medical needs and improve patient outcomes.
What is the highest forecasted price for ZURA Zura Bio Ltd.?
The highest price target for ZURA is $26.00 from at , which represents a 413.8% increase from the current price of $5.06.
What is the lowest forecasted price for ZURA Zura Bio Ltd.?
The lowest price target for ZURA is $11.00 from at , which represents a 117.4% increase from the current price of $5.06.
What is the overall ZURA consensus from analysts for Zura Bio Ltd.?
The overall analyst consensus for ZURA is bullish. Out of 4 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are ZURA stock price projections?
Stock price projections, including those for Zura Bio Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 9:26 AM UTC